Indivior PLC (INDV)

US — Healthcare Sector

Peers:

Automate Your Wheel Strategy on INDV

With Tiblio's Option Bot, you can configure your own wheel strategy including INDV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol INDV
Rev/Share 9.4726
Book/Share -2.3123
PB -6.0588
Debt/Equity -1.2937
CurrentRatio 0.8786
ROIC 0.2187

MktCap 1748027700.0
FreeCF/Share 1.0658
PFCF 13.2601
PE 622.7494
Debt/Assets 0.2691
DivYield 0
ROE -0.0121

Rating C-
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 1
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	INDV	Rodman & Renshaw	--	Buy	--	$16	Jan. 28, 2025

News

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

INDV
Published: June 19, 2025 by: PRNewsWire
Sentiment: Neutral

A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1 Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often affected by higher drug overdose death rates compared to other racial and ethnic groups2-5 RICHMOND, Va. , June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting.

image for news Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

INDV
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral

Indivior PLC (NASDAQ:INDV ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participants Carl Burns - Northland Capital Markets David Amsellem - Piper Sandler Christian Glennie - Stifel Chase Knickerbocker - Craig-Hallum Thibault Boutherin - Morgan Stanley Paul Cuddon - Deutsche Numis Operator Good day and thank you for standing by. Welcome to the Indivior PLC Q1 2025 Financial Results Conference Call.

image for news Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

INDV
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

INDV
Published: February 20, 2025 by: Benzinga
Sentiment: Negative

Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.

image for news European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

About Indivior PLC (INDV)

IPO Date 2014-12-29
Website https://www.indivior.com
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Joseph J. Ciaffoni
Employees 1030

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.